Kansas committee hears divided testimony on bill to let pharmacists initiate limited therapies
Loading...
Summary
The House Health and Human Services Committee heard proponent and opponent testimony on House Bill 2,676, which would allow pharmacists to initiate limited therapies (test-and-treat, emergency refills, minor ailments) under a standard-of-care framework. Supporters cited rural access and workforce shortages; medical society raised liability and scope concerns.
The Committee on House Health and Human Services heard testimony on House Bill 2,676, a proposal to allow licensed pharmacists in Kansas to initiate therapy for a narrow set of conditions consistent with their education, training and professional judgment. Reviser Carly summarized the bill’s core provisions, including four categories of pharmacist authority: care that does not require a new diagnosis, minor and generally self-limiting conditions, treatment guided by CLIA-waived tests, and patient emergencies.
Supporters told the committee the measure is a pragmatic response to access challenges in rural and underserved areas. Tim Frost, a licensed pharmacist and senior fellow with Cicero Action, said a standard-of-care approach is already in place in several states and argued the bill does not deregulate the profession. “This is not deregulation. This is outcome based oversight,” Frost said, citing Idaho, Colorado, Montana and Iowa as early adopters and pointing to workforce data he described as urgent: a projected shortage of more than 2,100 physicians by 2030, more than 250 primary care providers included in that deficit, and 71 of Kansas’s 105 counties designated as primary-care shortage areas.
Pharmacy regulators and educators also supported the bill. Alexanne Roblasi, executive director of the Kansas State Board of Pharmacy, told lawmakers the board has already overseen expanded pharmacy roles in Kansas — immunizations, point-of-care testing and collaborative drug therapy management — and would apply routine inspection and complaint processes to any expanded practice. “If any disciplinary action has occurred, I would note that that has been primarily related to record keeping,” Roblasi said, and emphasized the board’s ability to investigate complaints and take enforcement action.
Dr. Jim Backus, associate dean at the University of Kansas School of Pharmacy, and Tyler Woods of the Kansas Pharmacists Association emphasized pharmacist training and clinical experience, arguing that allowing pharmacists to practice at the top of their license would increase timely access to medication and preserve local health-care infrastructure.
Opponents focused on scope, safeguards and liability. Rochelle Colombo, executive director of the Kansas Medical Society, said the proposal is a significant expansion of prescriptive authority and urged limits — for example, excluding controlled substances and prohibiting remote pharmacies from implementing independent prescribing. Colombo urged additional statutory safeguards such as mandatory liability coverage and participation in the state health care stabilization fund, which she said would align pharmacist privileges with the requirements placed on other prescribers.
Committee members pressed proponents on several practical points: what constitutes a “new diagnosis,” how clinical records and HIPAA compliance would be handled, whether pharmacists would be expected to provide after-hours care, and how complaints or adverse outcomes would trigger board action. Proponents repeatedly pointed to the bill’s built-in constraints (CLIA-waived tests only for test-and-treat, limitation to minor or emergency scenarios, and anchoring to community standard of care) and to complaint-driven disciplinary enforcement.
The committee did not take final action on HB 2,676 during the hearing. The chair closed the hearing after extended questioning and public testimony; the bill remains under consideration by the committee.
